Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Inclusion Criteria:

- Male subjects diagnosed with haemophilia A without inhibitors present at screening and
currently treated on-demand

- Subjects with a baseline level of factor VIII below or equal to 2 % based on medical
records

- Age between 18 and 64 years both inclusive, at the time of signing informed consent

- Body weight between 50 and 100 kg, both inclusive

Exclusion Criteria:

- Known or suspected hypersensitivity to trial product or related products

- Platelet count below 50x10^9/L at screening

- Any clinical signs or known history of thromboembolic events, or subjects considered
at high risk of thromboembolic events as judged by the investigator

- Subjects at increased risk of cardiovascular disease as judged by the investigator